Precision BioSciences Inc. Stock News

Precision BioSciences Inc (NASDAQ: DTIL) announced additional data from its Phase 1/2a study evaluating PBCAR0191, off-the-shelf, allogeneic CAR T candidate targeting CD19. Data will be presented a

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 32.65% and 86.51%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

The stock price of Precision BioSciences Inc (NASDAQ: DTIL) increased by over 10% during intraday trading. This is why it happened.

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, announced today tha

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, today announced tha

DURHAM, N.C.--(BUSINESS WIRE)--Stanley R. Frankel, M.D. has been appointed to the Board of Directors for Precision BioSciences.

DURHAM, N.C.--(BUSINESS WIRE)--Derek Jantz, CSO and Co-Founder of Precision BioSciences, will participate in a fireside chat at Truist Securities Life Sciences Virtual Series.

Begins Search for Next Chief Executive Officer Begins Search for Next Chief Executive Officer

DURHAM, N.C., March 29, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies wi

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 12.00% and 136.97%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the sto

Shares of Precision BioSciences (NASDAQ:DTIL) moved higher by 2.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 22.22% year over year to

DURHAM, N.C., March 12, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company, today announced it will publish fourth quarter and fiscal year 2020

TransCode Therapeutics Starts $29 Million IPO Effort

Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Precision BioSciences Inc (NASDAQ: DTIL) has announced three-year follow-up data showing long-term stable reduction of low-density lipoprotein (LDL) cholesterol levels in nonhuman primates (NHPs)